JPRN-UMIN000050123招募中未知
Ripasudil-brimonidine fixed-dose combination Observational study to Confirm the safety and efficacy of rho Kinase inhibitor and alpha2 adrenergic receptor agonist for long-term use in Japanese patients with glaucoma - ROCK-alpha study
Japan society for Patient Reported Outcome0 个研究点目标入组 5,000 人开始时间: 2023年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who had used the ripasudil-brimonidine fixed-dose combination and had discontinued the use of it 2. Patients with a history of hypersensitivity to ripasudil or brimonidine 3. low birth weight infant, newborn infant, infant, or toddler who is younger than 2 years 4. Patients who need regal representatives to give their consent 5. Patients with other conditions that the investigators judge to be inappropriate for the study
研究者
相似试验
已完成
不适用
One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical TherapyPrymary open angle glaucomaJPRN-UMIN000026228Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokohama, Japan50
进行中（未招募）
1 期
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in newly diagnosed and uncontrolled hypertensive patients (PRECIOUS study)ewly diagnosed and uncontrolled patients with essential arterial hypertension.MedDRA version: 20.0Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2017-001596-23-HRKrka, d.d., Novo mesto471
进行中（未招募）
1 期
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in newly diagnosed and uncontrolled hypertensive patients (PRECIOUS study)ewly diagnosed and uncontrolled patients with essential arterial hypertension.MedDRA version: 20.0Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2017-001596-23-PLKrka, d.d., Novo mesto471
进行中（未招募）
1 期
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in newly diagnosed and uncontrolled hypertensive patients (PRECIOUS study)EUCTR2017-001596-23-SIKrka, d.d., Novo mesto461
进行中（未招募）
不适用
A Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane in Estrogen Receptor Positive Breast Cancer PatientsEUCTR2010-019867-13-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.350